作者将598名有狂犬病暴露史的成年患者随机分为A、B两组,其中A组299人在0、3、7天于两个三角肌部位皮内(ID)注射0.1ml纯化的Vero细胞狂犬病疫苗(PVRV),并在第28、90天于单部位ID注射1次;B组299人在0、3、7、14和28天于三角肌肌肉(IM)注射全剂量(0.5ml)PVRV.A组和B组中有WHO Ⅲ级狂犬病暴露者205人,在第1天又注射人狂犬病免疫球蛋白(HRIG)或马狂犬病免疫球蛋白(ERIG).同时作者又从兽医、护理学生和实验室工作人 The authors randomized 598 adult patients with a history of rabies exposure to A and B. Two of 299 patients in group A received intradermal (ID) injections of 0.1 ml of purified Vero cells on days 0, 3 and 7 Rabies vaccine (PVRV) and injected once at a single site ID on days 28 and 90; Group B, 299, received a full dose (0.5 ml) of deltoid muscle (IM) injection on days 0, 3, In Group A and Group B, there were 205 WHO grade 3 rabies exposures and HRIG or ERIG was also injected on day 1. At the same time, the authors also received veterinary and nursing students And lab workers